Drug safety sciences and the bottleneck in drug development
- PMID: 21593756
- DOI: 10.1038/clpt.2011.63
Drug safety sciences and the bottleneck in drug development
Abstract
During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability. The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment. The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position. If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion.
Similar articles
-
The marketplace can't give us the drug safety data we need.MedGenMed. 2007 Feb 9;9(1):29. MedGenMed. 2007. PMID: 17435636 Free PMC article. No abstract available.
-
Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.Drug Discov Today. 2011 Jan;16(1-2):73-80. doi: 10.1016/j.drudis.2010.11.006. Epub 2010 Nov 20. Drug Discov Today. 2011. PMID: 21094692 Review.
-
Operation of a radiopharmacy for a clinical trial.Semin Nucl Med. 2010 Sep;40(5):347-56. doi: 10.1053/j.semnuclmed.2010.06.002. Semin Nucl Med. 2010. PMID: 20674594
-
Adverse effects in women: implications for drug development and regulatory policies.Expert Rev Clin Pharmacol. 2011 Jul;4(4):453-66. doi: 10.1586/ecp.11.29. Expert Rev Clin Pharmacol. 2011. PMID: 22114855 Review.
-
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.Clin Cancer Res. 2006 May 15;12(10):2955-60. doi: 10.1158/1078-0432.CCR-06-0170. Clin Cancer Res. 2006. PMID: 16707588
Cited by
-
Human Multi-Lineage Liver Organoid Model Reveals Impairment of CYP3A4 Expression upon Repeated Exposure to Graphene Oxide.Cells. 2024 Sep 13;13(18):1542. doi: 10.3390/cells13181542. Cells. 2024. PMID: 39329726 Free PMC article.
-
Use of Drug Sensitisers to Improve Therapeutic Index in Cancer.Pharmaceutics. 2024 Jul 11;16(7):928. doi: 10.3390/pharmaceutics16070928. Pharmaceutics. 2024. PMID: 39065625 Free PMC article. Review.
-
Mapping Interindividual Variability of Toxicodynamics Using High-Throughput Transcriptomics and Primary Human Hepatocytes from Fifty Donors.Environ Health Perspect. 2024 Mar;132(3):37005. doi: 10.1289/EHP11891. Epub 2024 Mar 18. Environ Health Perspect. 2024. PMID: 38498338 Free PMC article.
-
Lobular distribution of enhanced expression levels of heat shock proteins using in-situ hybridization in the mouse liver treated with a single administration of CCl4.J Toxicol Pathol. 2024 Jan;37(1):29-37. doi: 10.1293/tox.2023-0053. Epub 2023 Oct 27. J Toxicol Pathol. 2024. PMID: 38283376 Free PMC article.
-
Synthesis and In Vivo Antiarrhythmic Activity Evaluation of Novel Scutellarein Analogues as Voltage-Gated Nav1.5 and Cav1.2 Channels Blockers.Molecules. 2023 Nov 3;28(21):7417. doi: 10.3390/molecules28217417. Molecules. 2023. PMID: 37959836 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical